Opus Genetics, Inc.
MERTK
inherited retinal disease
Countdown
542days
Phase 1 readout · ~ Dec 31, 2027 estimated
What's at stake
Phase 1 trial results for MERTK in inherited retinal disease are due ~ Dec 31, 2027. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“Q1 2027 MERTK clinical study initiation”